Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease

• DOI: 10.1002/alz.14602
• Publication Date: 2025-03-11T21:07:41Z
• Authors: Liwei Ma; Yihan Wang; Andrew Liem Hieu ...; Sanka Amadoru; Scott Wrigley; Paul Yates; Colin L. Masters; Benjamin Goudey; Liang Jin; Yijun Pan
• Keywords: Apolipoprotein E; Stroke; Angiopathy

Cerebral amyloid angiopathy (CAA) increases the risk of amyloid-related imaging abnormalities in Alzheimer's disease (AD) patients receiving anti-amyloid-beta therapies, emphasizing need to identify its factors. Data were collected from three cohort studies, and a machine learning model was developed predict CAA occurrence using selected The AD neuropathologic changes (ADNC)-CAA association significantly positive cross-sectional analysis. When stratified by factors, this generally stronger among females, smokers, people with history stroke/memory complaints, apolipoprotein E (APOE)-ε4 carriers, those without diabetes/heart conditions. In longitudinal analysis between potential factors CAA, higher observed males, older individuals, conditions, lower Mini-Mental State Examination (MMSE) scores, APOE-ε4 carriers compared their respective reference groups. Our study identified for cerebral angiopathy, informing prevention strategies. ADNC positively associated CAA. ADNC-CAA diabetes or heart Longitudinally, conditions/lower MMSE